Finding therapeutic antibodies that bind multiple related targets with high affinity and favorable biophysical properties remains challenging and resource-intensive. For snakebite antivenoms, this challenge is critical as treatments must neutralize toxins across multiple snake species. We developed a pipeline combining...
M. D. Overath, Suthimon Thumtecho, E. Rivera-de-Torre et al.· Science Advances· 0 citations
Generative protein design can now rapidly produce de novo binders with high affinity and functional activity against a wide range of targets, including lethal snake venom toxins. However, so far most reported successes rely on new-to-nature scaffolds with limited therapeutic precedent. Single-domain antibodies (VHHs) o...
M. D. Overath, Emil V. S. Lundquist, Kasper H. Björnsson et al.· bioRxiv· 0 citations
Odin-Multi is presented, a binder design framework that optimises a shared binder sequence against several complexes simultaneously, applying attractive objectives to on-targets and repulsive objectives to off-targets, and widens the range of binding behaviours accessible to computational design.
Valentas Brasas, C. R. Christensen, Kasper H. Björnsson et al.· bioRxiv· 0 citations
InstaNovo-FM is presented, a self-supervised foundation model for bottom-up proteomics trained to reconstruct masked regions of tandem mass spectra and establishes a unified representation space for peptide fragmentation spectra, enabling robust transferability across the proteomics ecosystem.
M. Nieuwoudt, Marco Reverenna, Divanisha Patel et al.· bioRxiv· 1 citation· ⚡1
Deep generative models have become a leading approach for designing therapeutic molecules, yet efficiently exploring vast biomolecular sequence spaces remains difficult, particularly for targets with limited training data. The prior distribution that seeds a generative model shapes which regions of sequence space it ex...
E. S. Engdal, Jonathan Funk, O. Bacarreza et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.